Showing 301 - 320 results of 342 for search '"Beverly Hills"', query time: 0.15s Refine Results
  1. 301
  2. 302

    Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction by Dell SJ, Gaster RN, Barbarino SC, Cunningham DN

    Published 2017-05-01
    “…Steven J Dell,1 Ronald N Gaster,2 Sheila C Barbarino,1 Derek N Cunningham1 1Dell Laser Consultants, Austin, TX, 2Gaster Eye Center, Beverly Hills, CA, USA Purpose: The aim of this study was to estimate the efficacy of intense pulsed light (IPL), followed by meibomian gland expression (MGX), for reducing the number and severity of signs and symptoms of dry eye disease (DED) secondary to meibomian gland dysfunction (MGD). …”
    Get full text
    Article
  3. 303

    Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line anti... by Juday T, Correll T, Anene A, Broder MS, Ortendahl J, Bentley T

    Published 2013-09-01
    “…Timothy Juday,1 Todd Correll,1 Ayanna Anene,2 Michael S Broder,2 Jesse Ortendahl,2 Tanya Bentley21Bristol-Myers Squibb, Plainsboro, NJ, USA; 2Partnership for Health Analytic Research LLC, Beverly Hills, CA, USABackground: February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line treatment of human immunodeficiency virus (HIV). …”
    Get full text
    Article
  4. 304
  5. 305
  6. 306
  7. 307

    Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide by Greene N, Higuchi K, Bognar K, Chang E, Broder MS

    Published 2022-12-01
    “…Nupur Greene,1 Keiko Higuchi,1 Katalin Bognar,2 Eunice Chang,2 Michael S Broder2 1Neurology & Immunology (N&I), Sanofi, Cambridge, MA, USA; 2Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USACorrespondence: Nupur Greene, Global HEVA Business Partner, N&I, Sanofi, 450 Water Street, Cambridge, MA, USA, Tel +1 857 259 0037, Email Nupur.Greene@sanofi.comPurpose: Multiple sclerosis (MS) is a costly, immune-mediated disease of the central nervous system. …”
    Get full text
    Article
  8. 308
  9. 309
  10. 310
  11. 311

    Facet-sparing lumbar decompression with a minimally invasive flexible MicroBlade Shaver® versus traditional decompression: quantitative radiographic assessment by Lauryssen C, Berven S, Mimran R, Summa C, Sheinberg M, Miller LE, Block JE

    Published 2012-07-01
    “…Carl Lauryssen,1 Sigurd Berven,2 Ronnie Mimran,3 Christopher Summa,4 Michael Sheinberg,5 Larry E Miller,6,7 Jon E Block71Tower Orthopedics, Beverly Hills, CA, USA; 2Department of Orthopedics, University of California, San Francisco, San Francisco, CA, USA; 3Pacific Brain and Spine, Castro Valley, CA, USA; 4The Spine Clinic of Monterey Bay, Soquel, CA, USA; 5Danville, CA, USA; 6Miller Scientific Consulting Inc, Arden, NC, USA; 7The Jon Block Group, San Francisco, CA, USABackground: Laminectomy/laminotomy and foraminotomy are well established surgical techniques for treatment of symptomatic lumbar spinal stenosis. …”
    Get full text
    Article
  12. 312
  13. 313
  14. 314
  15. 315
  16. 316

    Development of a Severity Classification System for Sickle Cell Disease by Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR

    Published 2020-10-01
    “…Nirmish Shah,1 David Beenhouwer,2 Michael S Broder,2 Lanetta Bronte-Hall,3 Laura M De Castro,4 Sarah N Gibbs,2 Victor R Gordeuk,5 Julie Kanter,6 Elizabeth S Klings,7 Thokozeni Lipato,8 Deepa Manwani,9 Brigid Scullin,10 Irina Yermilov,2 Wally R Smith8 1Department of Medicine, Duke University, Durham, NC, USA; 2Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA, USA; 3Foundation for Sickle Cell Disease Research, Hollywood, FL, USA; 4Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 5Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA; 6Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 7Department of Medicine, Boston University School of Medicine, Boston, MA, USA; 8Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; 9Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA; 10Department of Medicine, University of North Carolina, Chapel Hill, NC, USACorrespondence: Nirmish ShahDuke University, Department of Medicine, Duke South, Durham, NC 27710, USATel +1 (919) 668-5178Email nirmish.shah@duke.eduPurpose: There is no well-accepted classification system of overall sickle cell disease (SCD) severity. …”
    Get full text
    Article
  17. 317

    Long-term (60-month) results for the implantable miniature telescope: efficacy and safety outcomes stratified by age in patients with end-stage age-related macular degeneration by Boyer D, Freund KB, Regillo C, Levy MH, Garg S

    Published 2015-06-01
    “…David Boyer,1 K Bailey Freund,2 Carl Regillo,3 Marc H Levy,4 Sumit Garg5 1Retina-Vitreous Associates Medical Group, Beverly Hills, CA, 2Vitreous-Retina-Macula Consultants of New York, New York, NY; 3Wills Eye Institute, Philadelphia, PA, 4Sarasota Retina Institute, Sarasota, FL, 5The Gavin Herbert Eye Institute (University of California, Irvine) Irvine, CA, USA Background: The purpose of this study was to evaluate the long-term results of an implantable miniature telescope (IMT) in patients with bilateral, end-stage, age-related macular degeneration (AMD).Methods: A prospective, open-label, multicenter clinical trial with fellow eye controls enrolled 217 patients (mean age 76 years) with AMD and moderate-to-profound bilateral central visual acuity loss (20/80–20/800) resulting from untreatable geographic atrophy, disciform scars, or both. …”
    Get full text
    Article
  18. 318
  19. 319
  20. 320